Tumor microenvironment (TME) modulation is the therapeutic reprogramming of the cellular, stromal, and soluble networks surrounding a tumor to restore anti-tumor immunity and impair cancer progression. It targets immune, myeloid, stromal, and vascular axes rather than tumor cells alone.¹

Solid tumors evolve within an ecosystem that progressively shifts from immunosurveillance toward chronic immunosuppression. This shift is enforced by inhibitory immune checkpoints, dysfunctional myeloid populations, dense stromal architecture, and a suppressive cytokine milieu. Modulating these layers has become central to overcoming resistance to immune checkpoint blockade and other therapies.²

This page focuses on the mechanistic logic of TME modulation and the biological rationale for reshaping its key axes. For a foundational overview of TME components and their roles in cancer progression, see our companion page on the tumor microenvironment.

Immune suppression and exclusion

The TME suppresses immunity through coordinated mechanisms that disable effector function while reinforcing tolerance. Regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) dampen cytotoxic responses, while TGF-β, IL-10, and adenosine sustain an immunoregulatory milieu.³

Chronic antigen exposure drives CD8⁺ T cell exhaustion, characterized by sustained expression of inhibitory receptors such as PD-1, LAG-3, and TIM-3. Exhausted T cells progressively lose cytokine production and cytotoxic capacity. Metabolic constraints, including tryptophan depletion via indoleamine 2,3-dioxygenase (IDO) and lactate accumulation,further impair effector differentiation and persistence.⁴

Tumors are broadly classified by their immune phenotype: inflamed (T cell–infiltrated), excluded (T cells restricted to the stromal periphery), or desert (lacking T cells entirely). Immune exclusion reflects physical and chemokine-mediated barriers, whereas immune deserts often result from poor antigen presentation or defective priming.⁵

In excluded tumors, dense stromal architecture, aberrant vasculature, and TGF-β–driven cancer-associated fibroblast (CAF) activation impede T cell entry. Loss of effector-recruiting chemokines such as CXCL9 and CXCL10 further blocks infiltration. Restoring these gradients and normalizing the vasculature are key strategies for converting excluded tumors into inflamed, immunotherapy-responsive phenotypes.⁶

Myeloid cell targeting: TAMs and MDSCs

Myeloid populations dominate many solid tumors and act as central enforcers of immunosuppression. TAMs frequently adopt an M2-like, pro-tumorigenic phenotype, secreting IL-10, TGF-β, and arginase-1, which suppress T cell function and promote angiogenesis. MDSCs (heterogeneous immature myeloid cells) expand under tumor-derived signals and inhibit T and NK cell responses through ROS, arginase, and nitric oxide.⁷

Modulation strategies act along three biological axes: blocking myeloid recruitment, depleting suppressive populations, and reprogramming them toward immunostimulatory states. Disruption of the colony-stimulating factor 1 receptor (CSF1R) axis reduces TAM survival, while interference with the CCL2–CCR2 and CXCL12–CXCR4 chemokine axes limits monocyte and MDSC trafficking into tumors.⁸

Reprogramming approaches aim to shift TAMs from an M2-like to an M1-like phenotype, restoring antigen presentation and pro-inflammatory cytokine output. Activation of pattern recognition receptors,including Toll-like receptors (TLRs) and stimulator of interferon genes (STING), can re-educate myeloid compartments and enhance downstream dendritic cell maturation and T cell priming.⁹

Stromal and cytokine modulation

CAFs are principal architects of the stromal compartment, producing ECM components, matrix metalloproteinases, and immunomodulatory cytokines. They contribute to immune exclusion by depositing dense collagen networks and secreting TGF-β, which restricts T cell motility and promotes Treg differentiation.¹⁰

Increasing recognition of CAF functional heterogeneity has reshaped therapeutic thinking. Indiscriminate stromal depletion has produced paradoxical outcomes, including accelerated tumor progression, because certain CAF subsets restrain tumor growth. Subset-selective targeting — rather than broad stromal ablation — is therefore the current direction of the field.¹⁰

Cytokine modulation aims to rebalance the soluble milieu. Neutralization of TGF-β and IL-10 reduces tolerogenic signaling, while delivery of pro-inflammatory cytokines such as IL-2 variants, IL-12, and type I interferons enhances effector function. Engineered, tumor-selective cytokines are designed to localize immune stimulation while limiting systemic toxicity.¹¹

Vascular normalization offers a complementary axis. Anti-angiogenic modulation, particularly through VEGF pathway interference,can reduce hypoxia, improve perfusion, and facilitate lymphocyte infiltration. Combined with checkpoint blockade, this approach illustrates how stromal, vascular, and immune modulation converge to reshape the TME.¹²

The cancer-immunity cycle as a framework

The cancer-immunity cycle describes the stepwise generation and amplification of anti-tumor immune responses: antigen release, antigen presentation, T cell priming, trafficking, infiltration, target recognition, and tumor cell killing. Each step is regulated by stimulatory and inhibitory signals, and tumors evade immunity by disrupting one or more stages.¹³

Mapping TME modulation onto this cycle clarifies where interventions act:

• Antigen release and presentation: immunogenic cell death and STING activation enhance dendritic cell priming
• T cell priming and trafficking: chemokine modulation and vascular normalization restore effector recruitment
• Infiltration: stromal remodeling and CAF reprogramming overcome physical exclusion
• Recognition and killing: checkpoint blockade restores effector function at the tumor site¹⁴

Single-axis interventions often fail because tumors exploit multiple, redundant immunosuppressive mechanisms. Pairing modulators that target distinct steps of the cancer-immunity cycle — for example, combining checkpoint blockade with myeloid reprogramming or stromal modulation — addresses parallel resistance pathways. This rationale underlies the shift toward mechanism-guided combination strategies in immuno-oncology.¹⁵

Key regulatory nodes in TME modulation

• Checkpoint axes: PD-1/PD-L1, CTLA-4, LAG-3, TIM-3
• Myeloid axes: CSF1R, CCR2, CXCR4, TREM2
• Stromal axes: TGF-β, FAP⁺ CAF subsets, hyaluronan-rich ECM
• Metabolic axes: IDO, adenosine (CD39/CD73), lactate
• Innate immune activation: STING, TLRs, type I interferons

Frequently asked questions

References

1. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
3. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80.
4. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499.
5. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
6. Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548.
7. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498.
8. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–382.
9. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.
10. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–186.
11. Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15.
12. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics. Nat Rev Clin Oncol. 2018;15(5):325–340.
13. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
14. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188–2205.
15. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75–76.